Coeptis Therapeutics, Inc. (COEP)

USD 0.18

(-16.07%)

Market Cap (In USD)

7.28 Million

Revenue (In USD)

-

Net Income (In USD)

-21.26 Million

Avg. Volume

171.77 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.151-0.88
PE
-
EPS
-
Beta Value
-0.944
ISIN
US19207A1088
CUSIP
19207C104
CIK
1819663
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. David Mehalick
Employee Count
-
Website
https://coeptispharma.com
Ipo Date
2020-12-17
Details
Coeptis Therapeutics, Inc., a biopharmaceutical company, develops and commercializes generic and branded pharmaceutical products and cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a Vy-Gen drug product for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; and CD38-Diagnostic, an in vitro screening tool to provide the ability to pre-determine which cancer patients are most likely to benefit from targeted anti-CD38 monoclonal antibodies therapies. The company has collaboration with Statera BioPharma to develop and commercialize STAT-201 for Crohn's disease; and Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. Coeptis Therapeutics, Inc. was founded in 2017 and is headquartered in Wexford, Pennsylvania.